Skip to main content

Table 1 Adjustable maintenance dosing plan for active treatment or placebo administered via Turbuhalera during Weeks 5–52.

From: Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life

Adjustment

Criteria

Step up: from 1 or 2 inhalations/d to 4 inhalations BID (judged by the patient)

Two consecutive days or nights with: Rescue medication used ≥ 3 times during the day

OR

Night-time awakening due to asthma

OR

Morning PEF <85% of the mean of the last 7 days before Visit 3

Step down: from 4 inhalations BID to 1 inhalation BID after 7–14 days of step-up treatment (judged by the investigator)

Last 2 consecutive days or nights with:

No rescue medication use

OR

No night-time awakening due to asthma

OR

Morning PEF ≥ 85% of the mean of the last 7 days before Visit 3

  1. PEF = peak expiratory flow.
  2. aTurbuhaler is a trademark of AstraZeneca, Södertälje, Sweden.